Information for investors

Our business model is based on licensing our drug candidates to partners who further develop them and bring them to the market. We have multiple drug development projects underway, as well as collaborative projects with international biotech companies and academic research institutions.

Multiannual licensing agreements allow us to generate revenue during several years. Thus our aim is to create high business profitability in the long term.